Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The initial wave of excitement has now settled into a complex reality of access, affordability, and a sprawling, often confusing market
Sensing and signaling of oxidative stress in chloroplasts by inactivation of the SAL1 phosphoadenosine phosphatase
The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization
"For pharmaceutical executives, the lesson is clear: success in obesity will depend not only on science but also on vigilance, payer alignment, cultural reframing, and equitable access." The Evolution of Obesity Drugs: Lessons from a Century of Failures and the GLP-1 Breakthrough Thani Jambulingam, PhD The arrival of GLP-1 receptor agonists and dual agonists has delivered unprecedented efficacy, reframed obesity as a chronic disease, and sparked an industry gold rush
Some researchers prefer weekend mornings when potential side effects interfere less with work obligations
